| scholarly article | Q13442814 |
| P356 | DOI | 10.3109/10641950109152640 |
| P698 | PubMed publication ID | 12044312 |
| P2093 | author name string | A Eldor | |
| J B Lessing | |||
| A Many | |||
| A Bar-Am | |||
| G Fait | |||
| M J Kupferminc | |||
| D Yair | |||
| P2860 | cites work | A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase | Q24324172 |
| The factor V Leiden mutation may predispose women to severe preeclampsia. | Q34404132 | ||
| Underlying disorders associated with severe early-onset preeclampsia | Q40971826 | ||
| Preeclampsia: an endothelial cell disorder | Q41281924 | ||
| Inherited thrombophilia and pregnancy | Q41743292 | ||
| Low-molecular-weight heparin during pregnancy and delivery: preliminary experience with 41 pregnancies | Q44485657 | ||
| Small-for-gestational age births in successive pregnancy outcomes: results from a longitudinal study of births in Norway | Q44754659 | ||
| Low-molecular-weight heparin for obstetric thromboprophylaxis: experience of sixty-nine pregnancies in sixty-one women at high risk. | Q47309557 | ||
| Increased frequency of genetic thrombophilia in women with complications of pregnancy | Q47868847 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | heparin | Q190016 |
| thrombophilia | Q1570013 | ||
| prevention | Q1717246 | ||
| P304 | page(s) | 35-44 | |
| P577 | publication date | 2001-01-01 | |
| P1433 | published in | Hypertension in Pregnancy | Q5958696 |
| P1476 | title | Low-molecular-weight heparin for the prevention of obstetric complications in women with thrombophilias | |
| P478 | volume | 20 |
| Q37104719 | A descriptive evaluation of unfractionated heparin use during pregnancy |
| Q53086376 | Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomised trial. |
| Q64934667 | Antithrombotic prophylaxis for women with thrombophilia and pregnancy complications – Yes |
| Q44334947 | Association between the methylenetetrahydrofolate reductase C677T polymorphism and susceptibility to preeclampsia: the need for data clarification in a recent meta-analysis |
| Q38104276 | Association of microparticles and preeclampsia |
| Q58778341 | Can heparin prevent adverse pregnancy outcome? |
| Q28222450 | Dalteparin and low-dose aspirin in the prevention of adverse obstetric outcomes in women with inherited thrombophilia |
| Q36201389 | Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a prior history - an open-label randomised trial (the EPPI trial): study protocol |
| Q46187383 | Enoxaparin-metformin and enoxaparin alone may safely reduce pregnancy loss |
| Q35843645 | Fetal malformations and fetal death in a case of parental thrombophilia |
| Q37989428 | In vitro evidences of heparin's effects on embryo implantation and trophoblast development |
| Q38125276 | Inherited and acquired thrombophilias |
| Q35145560 | Inherited thrombophilia and poor pregnancy outcome |
| Q37892215 | Low molecular weight heparin in obstetric care: a review of the literature |
| Q47396374 | Low molecular weight heparin treatment during subsequent pregnancies of women with inherited thrombophilia and previous severe pregnancy complications |
| Q28538906 | Low-molecular weight heparin increases circulating sFlt-1 levels and enhances urinary elimination |
| Q37919870 | Maternal factor V Leiden and adverse pregnancy outcome: deciding whether or not to test |
| Q39448592 | Modulation of factors involved in placental haemostasis and angiogenesis by low-molecular-weight-heparins |
| Q33349894 | Molecular and vascular targets in the pathogenesis and management of the hypertension associated with preeclampsia |
| Q89227754 | Obstetric outcomes of recurrent pregnancy loss patients diagnosed wıth inherited thrombophilia |
| Q42787440 | Outcome of pregnancies in women with thrombophilic disorders |
| Q38206136 | Overview of low molecular weight heparin for preventative treatment of adverse obstetric outcomes related to abnormal placentation |
| Q81446389 | Pre-eclampsia |
| Q45117379 | Pregnancy loss, polycystic ovary syndrome, thrombophilia, hypofibrinolysis, enoxaparin, metformin |
| Q37810268 | Preventing thrombophilia-related complications of pregnancy |
| Q86295491 | Response to Xuan |
| Q40501138 | The Prevalence of Thrombophilia in Women With Recurrent Fetal Loss and Outcome of Anticoagulation Therapy for the Prevention of Miscarriages. |
| Q35007371 | The physiologic and therapeutic role of heparin in implantation and placentation |
| Q33343305 | The use of low-molecular-weight heparin for the management of venous thromboembolism in pregnancy |
| Q35134514 | Thrombocythaemia and pregnancy |
| Q37388698 | Thrombophilia and its impact on pregnancy |
| Q33339821 | Thrombophilia and its treatment in pregnancy |
| Q24801115 | Thrombophilia and pregnancy |
| Q28218550 | Thrombophilia and pregnancy complications: cause or association? |
| Q43295201 | Use of heparin in women with early and late miscarriages with and without thrombophilia |
| Q24632982 | VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines |
Search more.